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Abstract 
Schizophrenia is a genetically complex disease considered to have a neurodevelopmental pathogenesis 
and defined by a broad spectrum of positive and negative symptoms as well as cognitive deficits. 
Recently, large genome-wide association studies have identified common alleles slightly increasing 
the risk for schizophrenia. Among the few schizophrenia-risk genes that have been consistently 
replicated is the basic Helix-Loop-Helix (bHLH) transcription factor 4 (TCF4). Haploinsufficiency of 
the TCF4 gene causes the Pitt-Hopkins syndrome - a neurodevelopmental disease characterized by 
severe mental retardation. Accordingly, Tcf4 null-mutant mice display developmental brain defects. 
TCF4 associated risk alleles are located in putative coding and non-coding regions of the gene. Hence, 
already subtle changes at the level of gene expression might be relevant for the etiopathology of 
schizophrenia. Behavioural phenotypes obtained with a mouse model of slightly increased gene 
dosage and electrophysiological investigations with human risk-allele carriers revealed an overlapping 
spectrum of schizophrenia-relevant endophenotypes. Most prominently, early information processing 
and higher cognitive functions appear to be associated with TCF4 risk genotypes. Moreover, a recent 
human study unravelled gene*environment interactions between TCF4 risk alleles and smoking 
behaviour that were specifically associated with disrupted early information processing. Taken 
together, TCF4 is considered as an integrator (‘hub’) of several bHLH networks controlling critical 
steps of various developmental and possibly also plasticity related transcriptional programs in the CNS 
and changes of TCF4 expression appear to affect brain networks important for information processing. 
Consequently, these findings support the neurodevelopmental hypothesis of schizophrenia and provide 
a basis to identify the underlying molecular mechanisms. 
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Introduction 
Schizophrenia is still an unsolved genetic enigma. Although the disease is clearly heritable and great 
effort has been undertaken in the past decades to elucidate the genetic basis of this disorder, no major 
risk genes that would be suitable for prediction of the illness have been identified. The reason for this 
failure might arise from complex multigenetic interactions of risk alleles with minor individual 
contributions. It is also likely that a disease entity ‘schizophrenia’ does not exist behind the 
phenomenology-based disease classifications, which were useful for the clinical requirements but not 
for biological research. Thus, in the following text schizophrenia-spectrum disorder is meant when 
schizophrenia is written due to an improved readability. Nevertheless, in the last years some 
interesting and replicable findings with population-wide significance suggest that variations in a few 
genes might serve as risk markers at least in a subgroup of schizophrenia patients. Among the most 
validated genes is the basic Helix-Loop-Helix (bHLH) transcription factor 4 (TCF4). The preclinical 
and clinical findings regarding the connection between the TCF4 gene and schizophrenia will be 
reviewed and discussed in this contribution. 
 
The basic-Helix-Loop-Helix protein TCF4 
TCF4 belongs to the superfamily of bHLH transcription factors that can act as a transcriptional 
repressor or activator in a context specific fashion [1]. The bHLH domain comprises the basic region 
mediating DNA binding and a dimerization interface provided by the HLH domain with two 
amphipatic -Helices separated by an unstructured loop region forming left-turned four-helix bundles 
in dimers [2, 3]. bHLH proteins are involved in various developmental processes, including control of 
proliferation, determination of cell fate and specifications but have also been shown to be 
transcriptional integrators of adaptive cellular processes in terminally differentiated cells [1, 4–6]. 
TCF4 (also known as E2-2/SEF2, ITF2, ME2) is an ubiquitously expressed protein and subgrouped 
with two additional so-called E-proteins, TCF3/E2A and TCF12/HEB, as class I bHLH factors [2](for 
complete lists of gene name assignments see e.g., http://www.ihop-net.org or 
http://www.ncbi.nlm.nih.gov/gene). Ubiquitously expressed class I bHLH factors (TCF3, TCF4 and 
TCF12) are capable of forming homo-dimers and hetero-dimers with numerous cell-type specific (or 
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class II) bHLH and dominant-negative (or class V) HLH factors of the ID family (ID1-4) that lack a 
basic region and are therefore inhibiting DNA binding by sequestering bHLH factors [1]. 
Of particular practical importance is that the acronym or gene name alias TCF4 (TransCription Factor 
4) is unfortunately also widely used for T Cell Factor 4 (official gene symbol TCF7L2). TCF7L2 
belongs to the high mobility group (HMG) family of transcription factors and interacts with β-catenin 
of the WNT signaling pathway [7]. Therefore, greatest care should be taken when using software tools 
that automatically annotate key words from literature entries with ‘TCF4’ and when manually 
scanning the ‘TCF4’ literature. In consequence, the ‘bHLH-TCF4-schizophrenia and Pitt-Hopkins 
Syndrome (PTHS)’ related literature is likely to be contaminated by some false associations and 
authors, reviewers and readers should be sensible to this fact. To the best of our knowledge, we could 
not find evidence for a function of the bHLH factor TCF4 in glia/oligodendrocyte development, which 
was unfortunately mentioned in several previous reviews. 
 
Dimeric bHLH complexes bind to partially palindromic short DNA elements called Ephrussi-boxes 
(E-boxes) with the core sequence 5’-CANNTG-3’ located in regulatory regions [8]. For structural 
reasons, individual bHLH proteins display a preference towards particular E-box half-sites, which 
however, does not necessarily predict the exact binding site of a given hetero-dimer that can even vary 
at different sites of the genome [9]. Class II bHLH factors cannot form homo-dimers and exert their 
transcriptional function only in concert with a class I or E-protein such as TCF4 [1]. TCF4 may thus 
exert pleiotropic functions depending on its dimerization partner(s) at a given developmental stage and 
in a particular cell type. In consequence, TCF4 functions have been shown to be modulated by spatio-
temporal expression patterns of its various interaction partners, differences in DNA-binding 
specificities, by post-translational modifications and associated co-factors [10–13]. 
Mammalian E-proteins have been shown to at least partially complement for each other and gene 
dosage effects have been described in lymphocyte development that further enhances the pleiotropic 
functions of these genes and complicates the assignment of dedicated roles for individual E-proteins 
[14, 15]. In contrast to mammals, only one E-protein is found in Drosophila melanogaster and 
Caenorhabditis elegans, i.e. daughterless (da) and helix-loop-helix protein 2 (hlh-2), respectively. Still, 
the corresponding mutants revealed multiple phenotypes including deficits in nervous system 
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development indicating phylogenetic conservation of E-protein functions [16–18]. The human and 
mouse genes coding for TCF4 are located on chromosome 18 in both species. The mouse gene Tcf4 
encompasses >360 kB (chr 18E2, forward strand) and the human TCF4 >440 kB (chr 18q21.2, reverse 
strand)(www.ensembl.org, rel. 72). More than 18 coding splice variants with alternative N-termini 
have been described in humans [10] and the Ensembl genome browser (www.ensembl.org, rel. 72) 
lists 43 potentially protein encoding variants with the majority including the bHLH domain. Moreover, 
Sepp and colleagues [10] subgrouped 22 exons that are alternatively spliced particularly in the 5’ 
region with multiple alternative transcription initiation sites. Up to date, two putative antisense and 
one micro RNA transcripts (miR4529) have been annotated on the opposite strand within the human 
TCF4 locus (none so far in the mouse) potentially indicating regulation at the RNA level of increased 
complexity in the human genome. TCF4 mRNA abundance levels and/or control of translation may be 
regulated by complementary micro RNAs (miRs) shown to bind to the 3’ region of TCF4 transcripts 
including the schizophrenia-associated risk factor miR-137 as well as miR-155 and miR-204 [19–22], 
the number of predicted and, however, so far experimentally not validated binding sites for additional 
miRs is much longer [23]. Besides the C-terminal located bHLH domain, TCF4 shares with the other 
class I/E-proteins additional regions of homology including two more N-terminally located 
transcriptional activation domains (AD1 and AD2) [24, 25]. These domains have been shown to 
provide protein-protein-interaction surfaces to recruit chromatin remodeling complexes and 
transcriptional co-factors such as CBP/p300 [26, 27]. Moreover, TCF4 may be part of a SWI/SNF 
chromatin-remodeling complex which might be of relevance for the etiopathology of schizophrenia 
[28]. A knockdown of endogenous TCF4 in the human neuroblastoma cell line SH-SY5Y by siRNA 
altered the expression of multiple genes corresponding to various signalling pathways and affected cell 
survival, epithelial to mesenchymal transition and neuronal differentiation [29]. The siRNA approach 
yielded a highly efficient reduction of endogenous TCF4 protein to levels below 20%. Therefore, these 
findings that were obtained in a proliferating neuroblastoma cell line could be of relevance for PTHS, 
where a loss-of-function of TCF4 is most probable. Nonetheless, it is unclear, which bHLH interaction 
partners/dimeric complexes were affected in SH-SY5Y cells, e.g., affecting neuronal differentiation 
properties of this cell line and if these processes mimic developmental defects causing PTHS in vivo. 
Because of the presumably very subtle effects by the extragenic common alleles in TCF4 that have 
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been associated with an increased risk of schizophrenia, mechanistic studies with relevance for 
schizophrenia are most likely technically more challenging. 
In summary, the mammalian class I bHLH protein TCF4 can be considered as an integrator (‘hub’) of 
several bHLH networks controlling critical steps of various developmental and possibly also plasticity 
related transcriptional programs in the CNS (see Fig. 1). The deregulated splicing events and/or 
mRNA misexpression or altered stability of one or more distinct TCF4 protein isoform(s), which 
could be of particular relevance for schizophrenia are still unknown. 
 
Schizophrenia 
The main symptoms of schizophrenia can be distinguished into three major domains: 1) positive 
symptoms such as hallucinations, perceptual disturbances, delusional phenomena, and formal thought 
disorder; 2) negative symptoms mostly presented as flat affect, poverty of speech, avolition, 
anhedonia, lack of motivation, and inappropriate emotional responses; and 3) cognitive dysfunction 
including impairment of attention, memory, social cognition, and executive functions [30]. The 
highest risk period for developing schizophrenia is during young adulthood, while both sexes are 
equally affected by the disorder, although the age of onset is typically younger for men than women 
[31–33]. Although incidence rates vary depending on classification criteria, schizophrenia affects 
approximately 1% of the population across cultures [34, 35]. Individuals with parents or siblings 
suffering from schizophrenia have an increased risk for developing the disorder (8-12%). For 
monozygotic twins, the concordance rate is approximately 50% [36, 37]. The elevated familial 
incidence of schizophrenia strongly indicates that there must be a genetic contribution to the disorder, 
although the fact that concordance rates for monozygotic twins are lower than 100% suggests that 
environmental factors are also considerably involved. Thus, it is likely that a combination of genetic 
risk and environmental factors are required for the disorder to develop [37]. Initially, family-based 
linkage studies have identified several chromosomal regions and candidate genes that are associated 
with the risk for schizophrenia [38, 39]. However, none of the results of the linkage studies has passed 
a genome-wide significance level so far [40]. Subsequently, a multitude of association studies that 
were recently extended by genome-wide association studies (GWAS) identified only a few common 
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variants that contribute a very small increase in the susceptibility for schizophrenia [41–43]. Among 
the most replicable genes are the zinc finger binding protein 804A (ZNF804A), several genes from the 
major histocompatibility (MHC) region on chromosome 6, neurogranin (NRGN), and TCF4 [44]. Most 
recently, also several rare submicroscopic chromosomal alterations – called copy number variants 
(CNV) – have been detected to cause schizophrenia or schizophrenia-like symptoms (e.g., as the case 
in 22q11-syndrome) [43, 44]. However, these rare chromosomal abnormalities cannot explain the 
pathogenesis of the majority of schizophrenia patients and are often also associated with physical 
abnormalities and mental retardation. 
Although there is evidence for enlarged ventricles and decreased cerebral (cortical and hippocampal) 
volume associated with schizophrenia, there is not a distinct “diagnostic” neuropathology associated 
with the disease [38, 45, 46]. However, misplaced and clustered neurons, particularly in the entorhinal 
cortex, indicate problems of neuronal migration and suggest an early developmental anomaly [47–49]. 
Moreover, pyramidal neurons in the hippocampus and neocortex have been shown to have smaller cell 
bodies and fewer dendritic spines and dendritic arborizations and there are also reports of decreases in 
cell numbers in the thalamus and a decreased number of oligodendrocytes (reviewed in [39]. 
Additionally, decreased presynaptic proteins such as synaptophysin, SNAP-25, and complexin II have 
been observed in schizophrenia brains [50, 51] as well as decreased density of interneurons (e.g., 
parvalbumin-immunoreactive cells; [52, 53]. Neuroimaging data and post-mortem studies have shown 
that N-acetylaspartate (NAA), a marker of neuronal integrity, is decreased in first episode and never-
medicated patients [54, 55]. Based on these neuropathological changes, investigators have 
conceptualized schizophrenia as a disease of functional “dysconnectivity” [56–58], or a “disorder of 
the synapse” [59, 60] affecting the machinery of the synapse and subsequent neurotransmission [50, 
51]. 
Finally, accumulating evidence suggests that schizophrenia might be a neurodevelopmental disorder 
that is – at least in part – caused by aberrant early brain development that could be partially genetically 
determined: I.) Many schizophrenia patients exhibit delayed developmental milestones in childhood, 
including cognitive, motor, and behavioral abnormalities, which indicates abnormal brain function 
prior to diagnosis of schizophrenia, II.) obstetric complications and prenatal infections increase the 
risk for schizophrenia, III.) post-mortem studies did not find indicators for neurodegenerative 
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processes such as gliosis or loss of neurons in the brain of schizophrenia patients, and IV.) several 
anatomical and functional disruptions are associated with exacerbation of schizophrenia in adulthood 
and these disruptions can be simulated in developmental animal models [61, 62]. As suggested by 
Murray et al. [63], aberrant developmental processes may play a major role, especially in the 
congenital subform of schizophrenia that shows a gradual increase in behavioural disturbances until 
the disorder is diagnosed in adolescence or early adulthood. Maynard and colleagues [64] have 
proposed a two-hit hypothesis of schizophrenia. According to their suggestion a lesion occurring in 
early neurodevelopment (first hit), caused by genetic risk factors or adverse embryonic and perinatal 
events, in combination with a second hit, arising from hormonal events, excitotoxicity, psychosocial 
stress, or oxygen radical formation, may cause schizophrenia. Immunocytochemical and ultrastructural 
post-mortem studies have demonstrated neuronal alterations in schizophrenia, such as decreased size 
of the neuronal cell body, increased cellular packing density, fewer dendritic spines and synapses, and 
distortions in neuronal orientation [65]. The abnormalities in the cytoarchitecture, such as neuronal 
disarray, heterotopias, and malpositioning, indicate disruption of proliferation or migration at the 
gestational period [62]. In accordance, it was consistently shown that the expression of reelin, a 
glycoprotein that regulates neuronal migration, is strongly decreased in schizophrenia patients [66, 
67]. Thus, these morphological and cytoarchitectual changes are likely to arise during brain 
maturation. In sum, several lines of evidence suggest that abnormalities in brain development may 
contribute to the pathogenesis of schizophrenia at least in a subset of patients. 
 
Genetic association of TCF4 with schizophrenia 
Since 14 years chromosome 18 has been repeatedly proposed as a possible location for schizophrenia 
and bipolar disorder risk genes [68–72]. As bipolar disorder and schizophrenia show a high genetic 
correlation [73] it is not surprising that TCF4, which is located on this chromosome, was initially 
associated with bipolar disorder: The first study found that bipolar disorder was associated with a CTG 
triplet repeat expansion in an intronic region of the TCF4 gene [74]. The second study demonstrated 
that moderate expression of such repeats in this region was linked to severity of bipolar I disorder [75]. 
Subsequently, Pickard and colleagues [72] identified a pericentric inversion of chromosome 18 in a 
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small Scottish family whose members are suffering from mental retardation and schizophrenia and the 
breakpoint of this inversion was located close to the TCF4 gene. More recently, several large but also 
partially overlapping meta-analyses of GWAS consistently identified that common variants of the 
TCF4 gene contribute to the risk of schizophrenia (see also Table 1) [19, 76, 77]. In these analyses, 
two single nucleotide polymorphisms (SNPs) located in the intron located between the internal exon 4 
and internal exon 5 of human TCF4 gene according to the gene structure of Sepp et al., 2011 [10] (see 
below) on chromosome 18q21.2 (rs9960767, rs17512836) and an intragenic SNP near the TCF4 gene 
(rs4309482) have shown the strongest association with the disease [19, 76, 77]. All three GWAS meta-
analyses included data from the SGENE-plus study of schizophrenia, from the International 
Schizophrenia Consortium (ISC) and from the Molecular Genetics of Schizophrenia (MGS) group but 
the later reports of Steinberg et al. [77] and Ripke et al. [19] also included additional patient and 
control samples that are not overlapping. Additionally, three following studies replicated 
schizophrenia-TCF4 gene associations in independent samples: (1) A study in Han Chinese (in which 
the rs9960767 SNP is not polymorphic) identified a further intronic TCF4 SNP (rs2958182) that 
showed a significant association with schizophrenia [78]. (2) In a discovery sample from Ireland and a 
replication sample including non-overlapping samples from the Psychiatric GWAS Consortium 
(PGC), the SGENE-plus consortium and the Wellcome Trust Case Control Consortium 2 (WTCCC2), 
two intronic TCF4 SNPs (again rs9960767 and rs17594526, which was among the top ten significant 
TCF4 SNPs in the so far largest megalo-analysis of Ripke et al. [19] passed the significance threshold 
of p<5*10-8 [79]. (3) In a recent family-based linkage meta-analysis a further TCF4 SNP was 
identified (rs1261117) to be significantly associated with schizophrenia [80]. The use of the family-
based approach is a critical advantage here, given that all other GWAS employed only case-control 
designs that are susceptible for artefacts produced by population stratification [81], while using 
nuclear families in a replication study is robust against population stratification-induced false-positive 
findings [80].  
Moreover, in a phenotype-based association study applied to the German GRAS (Göttingen Research 
Association for Schizophrenia) sample, TCF4 rs9960767 (but not rs4309482) displayed some signal 
regarding a multivariate schizophrenia phenotype including PANSS positive and negative scores, a 
cognitive score, neurological soft signs, and age of prodromal onset [82]. Although the direction of the 
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effect was similar to previous GWAS (risk allele C was associated with a more pronounced 
phenotype) the association was not strong enough to pass multiple testing adjustments. In addition, a 
small post-mortem study suggested that at least the rs9960767 SNP is neither functional nor affects 
mRNA expression in the adult human brain indicating that such polymorphisms may yield their effects 
on gene expression through post-transcriptional pathways or in a developmental context by 
gene*environment interactions [41, 42]. In contrast, a more recent study reported that TCF4 
expression level in peripheral blood was significantly increased in patients with schizophrenia and 
bipolar disorder compared to controls. Additionally, peripheral TCF4 mRNA concentration was 
positively correlated with severity of positive and negative symptoms. However, TCF4 expression 
levels were only nominal and non-significantly correlated with some TCF4 SNPs that have not been 
named as schizophrenia risk variants so far [83]. In the same study, after correction for multiple testing 
more than 10 TCF4 SNPs, which have not been identified in previous GWAS, were significantly 
associated with expression of negative symptoms [83]. 
It was also investigated whether the TCF4 polymorphism rs9960767 modulates the response to 
antipsychotic drug treatment in schizophrenia but in two independent samples, comprising of more 
than 200 patients in total, the clinical improvement across four weeks was not influenced by TCF4 
genotype [84] suggesting that this TCF4 SNP is probably not a suitable predictor for antipsychotic 
drug effects. 
Taken these findings together, SNPs from the TCF4 gene together with common variants in the major 
histocompatibility complex (MHC) region are currently the best replicated schizophrenia susceptibility 
genes. However, the odds ratios for single variants are still small [OR around 1.2, see Table 1] and not 
useful for prediction of the disorder. Moreover, TCF4 SNPs cannot predict antipsychotic drug 
response so far. Thus, either TCF4 as well as the other schizophrenia risk genes only contribute a very 
small fraction to the total risk, together with many other genetic and environmental risks, or there is a 
distinct subpopulation of patients for which the TCF4 abnormalities might be major contributors to the 
etiopathogenesis of schizophrenia. 
 
TCF4, information processing, and cognition: Human studies 
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Already Kraepelin (1909) and Bleuler (1911) proposed that attentional and information processing 
deficits constitute core symptoms of schizophrenia [85, 86]. Following the early idea of Arvid 
Carlsson that schizophrenia might be a “thalamic filter deficit disorder” [87], impairments in early 
information processing have been repeatedly suggested to play a critical role in the pathogenesis of 
schizophrenia [88–91] Consequently, electrophysiological measures of early information processing – 
such as sensory gating or sensorimotor gating – have been proposed as promising behavioural 
endophenotypes of schizophrenia [92]. Such gating mechanisms have been conceptualized as 
important pre-attentive filter functions protecting cognitive processes from interfering with irrelevant 
information [93]. Schizophrenia patients and to a lesser extend also their unaffected first-degree 
relatives consistently display disrupted sensory and sensorimotor gating, commonly demonstrated by 
either lower P50 suppression of the auditory evoked potential (AEP) or reduced prepulse inhibition 
(PPI) of the acoustic startle response [88, 89, 94–100]. Both measures have been shown to be heritable 
and to be disturbed before onset of the illness [101–107]. Although sensory (P50 suppression) and 
sensorimotor (PPI) gating are conceptually related and both were parallel suggested as useful 
endophenotypes of schizophrenia they are not equivalent and usually also not correlated [94, 108–
110]. However, a recent meta-analysis confirmed that electrophysiological gating measures 
differentiate best between healthy individuals, relatives of schizophrenia patients and the patients 
themselves when compared to other proposed endophenotypes such as ventricle size, neurological soft 
signs or neuropsychological dysfunction [111]. 
As described above, transgenic mice moderately overexpressing Tcf4 in the postnatal brain display 
profound reductions in sensorimotor gating as measured by PPI [112]. Accordingly, the impact of the 
schizophrenia risk SNP TCF4 rs9960767 on PPI was investigated in human samples (Table 1). In fact, 
the risk allele C of this SNP was strongly associated with reduced sensorimotor gating in two 
independent samples of healthy volunteers and schizophrenia patients [113]. Interestingly, low PPI 
levels (>1.5 SD below normal) have shown a much stronger associations (OR=4.81) with the TCF4 
risk allele C than schizophrenia per se (OR=1.23) [76]. When considering effect size measures, a 
similar pattern arises: whereas the association of a diagnosis of schizophrenia with TCF4 genotype 
displayed only a very small effect size of w=0.09 [76], the association of the schizophrenia 
endophenotype PPI with TCF4 showed a strong effect size of d=0.90 averaged across both samples. 
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Impressively, of the 23 subjects carrying the C-allele across both investigated samples, 14 (61%) 
displayed low PPI levels (>1.5 SD below normal), when compared to the merged total sample, which 
is again an expression of the strong genotype effect of TCF4 on PPI. The authors hypothesized that the 
impact on PPI might arise from developmental changes of brain stem nuclei induced by the TCF4 
polymorphism (see Fig. 3 for an illustration of involved brain structures) [113]. 
Subsequently, we also investigated the influence of 21 TCF4 polymorphisms – which were most 
strongly associated with schizophrenia in a recent meta-analysis [19] – on sensory gating as assessed 
by P50 suppression of the AEP [114]. We used a multi-centre study done including six academic 
institutions throughout Germany with 1821 subjects (1023 never-smokers, 798 smokers) randomly 
selected from the general population (Table 1). Given that smoking is highly prevalent in 
schizophrenia [115] and was shown to affect sensory and sensorimotor gating [116] several 
parameters for smoking behaviour were additionally assessed. Like PPI also P50 suppression was 
significantly decreased in carriers of schizophrenia risk alleles of the TCF4 polymorphisms 
rs9960767, rs10401120, rs17597926, and 17512836 – the latter two were the most significant SNP in 
the mega-analysis of Ripke et al. [19]. Importantly, these gene effects were strongly modulated by 
smoking behaviour as indicated by significant interactions of TCF4 genotype and smoking status: 
heavy smokers (Fagerström score ≥4) showed stronger gene effects on P50 suppression than light 
smokers and never-smokers. Moreover, the genotype*smoking interaction seems to be dose-related as 
the TCF4 genotype effect grows with increasing smoking severity. Interestingly, TCF4 genotype 
effects on sensory gating were more evident at frontal (Fz) than vertex (Cz) electrodes. Previous 
studies reported that the prefrontal cortex substantially contributes either to the sensory gating process 
per se [117] or at least to the generation of the P50 amplitude [118]. Additionally, data from a recent 
EEG source localization study suggest that the sensory gating deficit of schizophrenia patients could 
be explained by dysfunction of the dorsolateral prefrontal cortex [41]. Thus, TCF4 mutations (in 
combination with smoking) might affect PFC function in schizophrenia. Accordingly, deficits of PFC 
functions have recently also been described in Tcf4tg mice [119]. 
In conclusion, these results imply that the schizophrenia risk alleles of TCF4 variants interact with 
smoking behaviour with regard to auditory sensory gating. However, if smoking behaviour strongly 
modulates the TCF4 genotype effects on a proposed endophenotype of schizophrenia it might also 
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modulate the risk for schizophrenia itself. We therefore suggested the investigation of potential 
moderating effects of dimensional and binary measures of smoking behaviour on genetic risk factors 
of schizophrenia. In fact, preliminary data from 882 schizophrenia patients and 2163 controls now 
suggest that the risk allele C of the TCF4 rs9960767 is indeed more frequent in smoking schizophrenia 
patients (8.3%) than in non-smoking patients (5.3%) or smoking (5.5%) and non-smoking controls 
(5.8%) transferring in an OR of 1.55 for smoking patients in contrast to OR of 0.90 for non-smoking 
patients (personal communication Dan Rujescu, University of Munich, Germany, unpublished data). 
These results have certainly to be replicated in further and larger samples but nevertheless these data 
indicated that stratification for smoking behaviour in case-control association studies potentially adds 
power resulting in stronger gene effects. Moreover, it should be further explored if nicotine use itself 
might enhance the risk for schizophrenia as indicated by longitudinal studies showing that beyond 
cannabis and alcohol use also early consumption of tobacco increases the risk for psychosis [120, 
121]. Finally, an extended endophenotype including electrophysiological gating measures such as PPI 
or P50 suppression, smoking behaviour, and risk genes such as TCF4 may be suitable as an early 
indicator for a developing psychosis [114]. Moreover, dedicated gene*environment studies could be 
performed in mouse models providing additional evidence for TCF4*smoking interactions and 
allowing the investigation of underlying molecular mechanisms. 
 
Neurocognitive dysfunctions have been proposed as promising endophenotypes of schizophrenia as 
well [122]. In particular, impaired verbal memory, which is among the most prominent and 
consistently reported cognitive deficits of schizophrenia [123], has been emphasized as a potential 
intermediate schizophrenia phenotype as studies with unaffected relatives from multiple affected 
families (“multiplex families”) and twin studies demonstrated an increasing memory deficit along with 
an increasing genetic load [124–126]. Lennertz et al [127] therefore investigated the impact of the 
TCF4 rs9960767 variant on verbal memory performance in a sample of 401 schizophrenia patients 
[127]. While no effect of the schizophrenia risk allele C on immediate recall and total learning was 
found, a weak trend regarding delayed verbal memory appeared surprisingly indicating superior 
performance in carriers of the risk allele compared to non-carriers. Moreover, in the cued recall 
condition (word recognition) schizophrenia patients carrying at least one C-allele significantly also 
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recognized more words compared to patients without the risk allele. These results were unexpected 
considering the supposed impact of TCF4 on brain development and assuming that an endophenotype 
should display a similar association with the risk gene (e.g., impaired memory in carriers with the 
schizophrenia risk gene) as an endophenotype with the complex disease phenotype (e.g., memory 
deficit in schizophrenia patients). Given that the effects sizes of the genotype effects were rather small 
(Cohen’s d=0.34, after correction for several covariates d=0.27) and that the results would not have 
become significant if the statistical threshold would have been corrected for multiple test parameters, 
these results should not be over-interpreted. These authors also explored functional effects of the same 
TCF4 variant on a comprehensive neuropsychological test battery in a sample of about 200 
schizophrenia patients and a control sample of 205 healthy volunteers [127]. The assessed cognitive 
functions attention and vigilance, working memory, processing speed, visuo-motor speed and set-
shifting, as well as verbal fluency were all unaffected by TCF4 rs9960767 in both groups (unpublished 
data). Thus, although haploinsufficiency of the TCF4 gene is associated with severely disrupted 
intellectual functions as presented in the PTHS, no considerable effect of the TCF4 rs9960767 
polymorphism on neuropsychological function was found in this sample with exception of a weak and 
unexpected association with word recognition (Table 1). 
In contrast, Wirgenes et al. recently reported from a large sample of patients with schizophrenia 
spectrum disorders (total n=596 including patients with schizophrenia, bipolar disorder, other 
psychoses) and healthy controls (n=385) that the risk alleles of the TCF4 risk variants rs12966547 and 
rs4309482 were associated with worse verbal fluency in the total sample [83]. They found also some 
trends that the schizophrenia risk alleles from rs43094882 and rs9960767 were associated with 
ventricular and/or hippocampal volume but these results did not survive correction for multiple testing. 
In the exploratory analyses, there were also some significant associations of other TCF4 SNPs with 
verbal learning, executive functioning, and several brain abnormalities [83]. 
A study in Han Chinese investigated the impact TCF4 rs2958182 SNP, previously associated with 
schizophrenia in the same ethnicity [78], on cognitive functions in 580 schizophrenia patients and 498 
controls [128]. The authors reported that the schizophrenia risk allele was associated with better 
performance in patients but worse performance in controls regarding an IQ test as well as in attention-
related tasks. Because of this unexpected result pattern, the authors speculated that TCF4 and 
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cognition might follow an inverted U-shaped function. However, it is not fully clear at the moment, if 
previous European studies and this Chinese study can be adequately compared.  
Most recently, a Canadian study explored the association of the TCF4 rs9960767 SNP with 
neurocognitive function in 173 first-episode psychosis patients (affective and non-affective psychosis). 
The authors reported that carriers of the rs9960767 C allele performed worse in the cognitive domains 
of “reasoning and problem solving” and “speed of processing” adumbrating that TCF4 polymorphisms 
might contribute also to deficits in higher cognitive function in schizophrenia patients [129]  
In a lymphocyte-based gene expression study in healthy Mexican Americans, it has been recently 
shown that peripheral expression of TCF4 – among seven further genes (IGFBP3, LRRN3, CRIP2, 
SCD, IDS, GATA3, and HN1) – predicted cortical grey matter thickness measured with magnet 
resonance tomography [130]. Notably, TCF4 expression was correlated particularly with grey matter 
thickness in the prefrontal cortex. The authors concluded that a progressive decline in the regenerative 
capacity of the brain contributes to normal cerebral aging including thinning of the grey matter [130]. 
A critical role of TCF4 specifically for development of the prefrontal cortex was also supported by 
recent post-mortem data showing a significant association between TCF4 expression and cis eSNPs 
(previously identified in an expression quantitative trait loci analysis) in tissue of the prefrontal cortex 
(rs1261085, rs1261134, rs1261073) and the thalamus (rs1261134), while in the hippocampus, 
temporal cortex and cerebellum no such associations were found [131]. 
 
Taken the human gating and cognition data together, it appears that TCF4 SNPs likely affect early 
information processing in that way that schizophrenia risk alleles are consistently associated with a 
schizophrenia-like phenotype, i.e. reduced gating functions (for an overview see Table 1). At least the 
effect for auditory sensory gating was strongly modulated by smoking suggesting a possible 
gene*environment interaction that might be also relevant for the development of schizophrenia. There 
are also initial data arguing that common TCF4 variants might have an impact on brain morphology 
specifically regarding the prefrontal cortex, which is also in line with the impact on gating functions 
that might involve the prefrontal cortex and also in accordance with neurodevelopmental phenotypes 
obtained with Tcf4 and neuronal bHLH mouse models as discussed above. Whether common TCF4 
variants also influence higher cognitive functions in healthy volunteers or schizophrenia patients is not 
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clear at the moment as existing studies are controversial, present rather weak associations, and are 
currently not replicated. In contrast, more severe TCF4 mutations, as occurring in the PTHS, are 
definitely accompanied with strong cognitive dysfunction suggesting that a considerably disturbed 
TCF4 function is associated with strong changes in brain development (see following section).  
 
TCF4 and neurodevelopmental disorders 
Heterozygous hypomorphic, null mutations or deletion (haploinsufficiency) of the TCF4 gene in 
humans causes the rare PTHS – an autosomal-dominant neurodevelopmental disorder characterized by 
severe mental, motor and language retardation, epilepsy, facial dysmorphisms, intermittent 
hyperventilation, and rarely also postnatal microcephaly –, pointing to the fact that TCF4 is critical 
also for normal development of the mammalian nervous system (Forrest et al., 2012; de Pontual et al., 
2009; Sweatt, 2013; Zweier et al., 2007). Currently, only 200-300 diagnosed cases with PTHS exists 
worldwide (Sweatt, 2013). A small proportion of patients suspected to have the Angelman syndrome, 
which displays a similar phenotype as PTHS and also have mutations in the TCF4 gene [136]. A 
recent study with 10 young PTHS patients revealed strong intellectual and motor disabilities together 
with a behavioral phenotype that overlaps with autism spectrum disorders [137]. The autism-like 
behaviour was characterized by difficulties in engaging and communicating with others, frequent 
occurrence of repetitive motor stereotypies, repetitive play and fascination with specific objects, and 
difficulties with changes in daily life routines. The real age of the PTHS patients ranged from 32 to 
289 months whereas the estimated developmental age lied between 3.5 months and 15 months for the 
mental abilities and between 4 months and 19 months for the motor abilities [137]. Notably, in a 
recent study investigating balanced chromosomal abnormalities in patients with autism convergent 
genomic information suggested that the TCF4 gene might also be involved in the pathogenesis of 
autism-spectrum neurodevelopmental disorders [138].  
Surprisingly, prominent macroscopic brain abnormalities are not common in PTHS: only subtle 
hypoplasia of the corpus calossum has been consistently reported [139–141], while also enlarged 
ventricles (similar to schizophrenia, [142] and thin hindbrain [140, 141] as well as enlarged caudate 
nuclei and a lower hippocampus volume have been reported [143]. Whalen et al estimated that only 
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about 50% of the PTHS patients display abnormalities in structural brain imaging, while only about 
7% reveal a microcephaly Whalen et al (2012) .  
 
Tcf4/TCF4 expression in brain development  
The function of TCF4  in nervous system development and adult brain must be seen in the context of 
its numerous proposed and few experimentally validated interaction partners of the bHLH family (see 
Fig. 1) and its complex spatio-temporally regulated expression pattern. All E-proteins are expressed 
during embryonic stages including neural structures (http://www.brain-map.org/) with Tcf4/TCF4 
showing the highest expression levels in mouse and human brain tissue (http://www.brainspan.org/) 
[13, 144]. In contrast to Tcf3 and Tcf12, Tcf4 expression remains at substantially high levels in the 
adult and aged rodent brain [112, 145, 146]. Tcf4 expression is sustained particularly in areas of high 
neuronal plasticity such as the cerebral cortex, hippocampus and cerebellum [13, 112]. Human TCF4 
expression has been detected in the prosencephalon and the ventricular zone of the embryonic CNS 
[133], in the telencephalon at all stages of fetal development as well as in the adult forebrain 
(http://www.brainspan.org/). In summary, TCF4 is the only E-protein being expressed at all stages in 
the developing and adult mouse and human brain. 
In contrast to the constitutive and broad expression of Tcf4, all putative interaction partners in the 
nervous system show a much more spatio-temporally restricted expression profile (Fig. 1). The 
expression of the bHLH inhibitors Hes1 and Id1 are transiently expressed in embryonal stages and 
their function indeed seems to be confined to inhibit premature differentiation initiation [147, 148]. 
Neurogenesis associated pro-neuronal class II bHLH proteins of the achaete scute (e.g., 
ASCL1/MASH1), atonal (e.g., ATOH1/MATH1) and neurogenin families (NEUROG1,2) are 
transiently expressed at early stages of development whereas the gradual onset of expression of group 
II bHLH proteins involved in terminal neuronal differentiation (e.g., NEUROD family members 
NEUROD1, -2, and -6) is confined to later stages and remains sustained in the adult brain [5, 149]. All 
type II neuronal bHLH proteins are thought to depend on the hetero-dimerization with an E-protein 
[1]. Thus, at least in later stages of neuronal differentiation and selected brain regions, TCF4 appears 
to be the obligate interaction partner of neuronal class II bHLH proteins. This selective availability as 
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unique interaction partner may explain dosage susceptibility of TCF4 observed in genetic model 
systems such as zebrafish [150] and mouse [151] and in human patients suffering from PTHS (Sweatt, 
2013) and potentially also schizophrenia (see below). 
 
Tcf4 functions in neurodevelopment and cognitive processing: lessons from 
mouse models 
Tcf4 heterozygous null mutant mice (Tcf4+/-) are viable, fertile and display no obvious phenotype 
[151]. Although subtle defects cannot be excluded so far, Tcf4+/- mice do not replicate the profound 
effects observed in humans where haploinsufficiency causes severe developmental disturbances 
including PTHS phenotype (Fig. 2 and see below). As reported by Zhuang et al. [15, 152], Tcf4 
homozygous null mutant mice (Tcf4-/-) were born with extremely low frequency and did not survive 
longer than one week after birth. In contrast, Flora et al. [151] did not observe embryonic lethality of 
null mutants and obtained expected Mendelian ratios of Tcf4-/- mice at birth; however, animals died 
within the first 24h. Nevertheless, both studies showed that the complete inactivation of both Tcf4 
alleles has strong developmental consequences in mice with evident morphological defects detected so 
far only in pontine nuclei development, which has been specifically attributed to the interaction of 
TCF4 with the proneural transcription factor ATOH1/MATH1 [151]. Therefore, in mice TCF4 
function during early brain development may be partially compensated by the other class I bHLH 
factors TCF3 and TCF12. However, in mosaic Tcf4+/- Tcf4-/- mice only pups displaying maximal 
proportion of 30% of Tcf4 null cells are viable [153]. Nonetheless, conditional knockouts enabling 
targeted deletions at various stages of CNS development will be essential to better understand more 
subtle phenotypes possibly caused by the loss of function of Tcf4. Such mouse models may allow 
studying embryonal TCF4 dysfunction even in the adult brain without being hampered by embryonic 
or perinatal lethality.  
So far, insight about the role of TCF4 on adult brain function in the mouse is restricted to a model with 
slightly increased expression levels in the forebrain [112]. In addition to loss-of-function models (see 
above), gain-of-function studies may be of particular relevance for schizophrenia as TCF4 mRNA 
expression is significantly increased in post-mortem cortical samples and peripheral blood cells of 
  19
psychosis patients [83, 154]. Furthermore, TCF4 mRNA expression level is elevated in neurons 
derived from human induced pluripotential stem cells of schizophrenia patients versus unaffected 
subjects [155]. Therefore, Thy-1 promoter driven overexpression of Tcf4 mRNA in brain structures 
involved in cognition such as the cortex and hippocampus of the mouse [112] may partially replicate 
molecular alterations of increased schizophrenia risk in humans. Subsequently, we will refer to these 
mice as Tcf4tg. The onset of transgenic Tcf4 expression is confined to early postnatal stages and 
neither breeding problems nor any overt abnormalities’ have been observed. Nonetheless, adult Tcf4tg 
mice displayed profound deficits in contextual and cued delay fear conditioning indicating 
hippocampal deficits. Alterations in activity, anxiety or exploratory drive were not observed, thus 
postnatal Tcf4 overexpression affected only early information processing and cognitive functions 
[112]. Fear associated learning deficits were erased upon applying stronger aversive stimuli arguing 
for a subtle defect [112]. In addition, Tcf4tg mice display deficits in trace fear memory most likely 
paralleled by reduced levels of attention and behavioural anticipation [119]. It has been shown that 
these higher order cognitive processes depend both on the hippocampus and the anterior cingulate 
cortex (ACC) [156]. Thus, impaired interactions between the prefrontal cortex and the hippocampus 
likely contribute to the reduced cognitive performance in Tcf4tg mice. Similar disturbances between 
remote brain regions have been described in the Df(16)A+/– strain that harbor a microdeletion in mice 
corresponding to a human chromosome 22 (22q11.2) deletion described in schizophenia [157]. 
Moreover, altered functional cortical-hippocampal connectivity has been frequently reported in 
schizophrenia patients [158, 159]. In addition, Tcf4tg mice display sensorimotor gating deficits 
correlating with a frequent endophenotype of SZ patients [88, 107, 160–162]. In summary, the 
analysis of Tcf4tg mice has provided accumulating evidence to support the role of TCF4 in brain 
circuits involved in cognition and higher order information processing, which is independently 
strengthened by human studies (Fig. 3 and see below). 
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Discussion 
The schizophrenia associated gene TCF4 belongs to a subfamily of bHLH transcriptional factors that 
recognize E-box binding sites on regulatory DNA elements in the genome [1, 8]. At early 
developmental stages class I / E-protein transcription factors such as Tcf3, Tcf4, and Tcf12 show wide 
expression throughout the brain but only Tcf4 displays sustained expression in the adult brain of mice, 
which is most prominent in the cerebellum, hippocampus, and cortex [112, 145]. In conclusion, TCF4 
is at least during later stages of neurodevelopment and in the adult brain the obligate interaction 
partner of multiple class II neuronal bHLH factors of e.g., the NEUROD family [112]. Therefore, 
TCF4 must be considered as an interaction ‘hub’ in neuronal bHLH protein networks important for 
different aspects of neurodevelopment and adult plasticity [149, 163]. Due to potentially competing 
functions, it is retrospectively not surprising that control of TCF4 gene dosage and protein function, in 
contrast e.g., to other neuronal bHLH factors, is particularly susceptible to interference. Thus, TCF4 
availability for unknown homo- and/or heterodimeric bHLH complexes represents a critical bottleneck 
in neurodevelopmental processes that might be associated with an increased risk of schizophrenia. 
Reduced TCF4 activity (haploinsuffiency) has been shown to cause severe mental retardation as 
observable in the PTHS and may also be associated with other autism-spectrum disorders in humans 
[134, 138]. More subtle gene dosage alterations are likely to be associated with schizophrenia and 
possibly also bipolar disease. Gene dosage sensitivity may not be as pronounced in rodents compared 
to humans as heterozygous null mutant mice display only subtle neurodevelopmental disturbances 
although for example a thorough behavioural analysis of these mice is still missing [151].  
 
Given the enormous complexity of TCF4 splice variants and biochemical properties of different PTHS 
associated mutations [10, 11], it is still possible that dominant-negative effects beyond dosage effects 
contribute to the severity of the neurodevelopmental disturbances in humans. In a transgenic mouse 
model (Tcf4tg) with slightly elevated expression of Tcf4 in the forebrain and displaying cognitive and 
sensorimotor deficits were observed supporting the critical gene dosage sensitivity [112]. However, 
potentially dominant negative effects by the corresponding C-terminally tagged protein expressed in 
the transgenic animals cannot be formally excluded since C-terminal frame shift mutations have been 
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shown to alter TCF4 functions [11]. Nonetheless, Tcf4tg mice display a dysbalance of Neurod1 versus 
Id2 expression ratios and it is thus plausible, that even slight disturbance of a delicate balance of 
bHLH transcription factor gene expression in the adult brain impairs cognition and information 
processing. In line with that, heterozygous Neurod2 null mutants also display cognitive deficits [164]. 
Notably, the dominant HLH factors Id2 and Id4 display similar to Tcf4, Neurod2 and Neurod6 
sustained expression in the adult brain indicating a dynamic control of adult TCF4 function at the level 
of dimerization possibly coupled to neuronal activity possibly via nuclear Ca2+ signalling. It has been 
shown that TCF4 interacts with the Ca2+ binding protein calmodulin at physiological concentrations 
inhibiting DNA binding of E-protein homodimers in non-neuronal cells [165–169]. The mode of the 
Ca2+ mediated regulation of TCF4 function in neurons is not known but should, for several reasons, be 
of high interest for future attempts to understand the mechanisms of how TCF4 contributes to 
endophenotypes of schizophrenia. Firstly, localized Ca2+ signalling has been identified as a key player 
in communicating synaptic activity to the nucleus and to be critically involved in mediating 
transcription dependent adaptive responses in neurodevelopment, plasticity and cognitive processes 
[170, 171]. Secondly, recent cross-disorder analyses of GWAS data combined with pathway analysis 
provided strong evidence for the importance of L-type voltage gated Ca2+ channels (VGCC) and Ca2+ 
signalling in schizophrenia and bipolar disorders [172]. Most prominently, The intronic 
polymorphism rs4765914 in CACNA1C has been previously associated independently with bipolar 
disorder [173, 174], schizophrenia [19] and major depressive disorder [175]. Genetic imaging 
approaches linked CACNA1C variants along an endophenotypic spectrum similar to that observed for 
TCF4 including attention deficits [176] and memory formation [177]. Of note, the C-terminus of 
CACNA1C encodes a transcription factor that is implicated in activity-transcription coupling by 
regulated proteolysis at the membrane [178]. Moreover, several other Ca2+ regulated transcription 
factors (CREB1, MECP2, MEF2, FOSB, NPAS4, CREST among others) have been associated with 
psychiatric diseases such as Rett-Syndrome, autism and bipolar disorder [170, 171, 179]. In addition, 
the validated TCF4 interaction partners NEUROD1 and NEUROD2 are themselves regulated by Ca2+ 
[179–182]. Although there is no direct experimental evidence for a particular mechanism by which 
synaptic activity/Ca2+ could modulate TCF4 activity in neurons, several non-exclusive modes of action 
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are possible that are based on studies with different class I and II bHLH factors in non-neuronal cells 
(see above): (i) Regulation of transcription or splicing of TCF4 or its interaction partners by Ca2+ 
regulated transcription or splicing factors, (ii) Ca2+ controlled cytoplasm to nucleus shuttling of TCF4, 
(iii) modulation of dimerization selectivity and DNA binding efficiency or specificity by either 
interaction with Ca2+ binding proteins such as calmodulin or posttranslational modifications via Ca2+ 
regulated kinases, which could also alter (iv) the recruitment of transcriptional co-factors such as 
p300/CBP, (v) transcriptional regulation of gene products involved in Ca2+ signalling. 
The importance of a tightly controlled gene expression program in the context of schizophrenia is 
further supported by the findings that mirR-137 is also a genetic risk factor and has been shown to 
target 3’ regions in the human mRNA of TCF4 [22]. Due to the promiscuity of micro RNAs, it is not 
surprising that miR-137 most likely regulates abundance levels of several mRNAs among which, 
however, may be a substantial fraction of schizophrenia risk associated gene products [183]. Similar 
to TCF4, miR-137 has been shown to be involved in the regulation of neuron maturation [184] and 
adult neurogenesis [185]. Most recently, a post-mortem study demonstrated that a decreased miR-137 
expression – caused by the TT genotype of the SNP rs1625579 – was associated with increased TCF4 
expression [154]. Although the identification of putative miR-137 targets is mainly based on in silico 
predictions and has only partially been validated by reporter gene assays, it is possible that mir-137 
also represents another ‘hub’ within gene regulatory programs that are considered to be of particular 
relevance for schizophrenia. Among the putative mir-137 targets beyond TCF4 are several high 
confidence schizophrenia risk genes (CSMD1, C10orf26, CACNA1C, and ZNF804A) and members of 
schizophrenia-associated glutamatergic, GABAergic, serotonergic, and neuregulin-ErbB signaling 
pathways (GRIN2A, GRM5, GABRA1, HTR2C, NRG2, NRG3 ERBB4) [183]. Although direct target 
genes of TCF4 in the brain are not known and putative mir-137 targets have not been validated in vivo, 
growing evidence suggests that both factors are crucial players of gene expression networks that may 
be particularly susceptible to interference by environmental factors. In schizophrenia, multiple genes 
are thought to cooperate with different environmental factors in unfavourable combinations. Thus, 
future research should be dedicated to the elucidation of TCF4 and miR-137 controlled gene regulatory 
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networks that may allow the elucidation of causal gene*interactions underlying schizophrenia 
symptoms. 
 
It has been proposed that the inter-individual phenotypic variability and severity of PTHS may reflect 
the molecularly divergent mutations that compromise TCF4 function differentially [11]. Similarly, we 
hypothesize that a graded level of ‘severity’ of TCF4 dysfunction ranging from haploinsufficiency 
caused by missense mutations in PTHS [134, 135], to chromosomal aberrations [138], and subtle 
alterations induced by common genetic variants [19, 76, 77] correlates with the ‘severity’ of the 
corresponding neurodevelopmental diseases such as mental retardation, autism-spectrum disorders and 
schizophrenia. The most obvious common feature of these diseases is the graded intellectual and 
cognitive impairment. As described above, accumulating data from both human and mouse studies 
suggests that TCF4 dysfunction might be particularly important for higher order cognitive processing. 
Therefore, it may be possible that overlapping mechanisms and/or pathways are affected by TCF4 
which could have implications for the focus of future experiments. Assuming that similar mechanisms 
are rather quantitatively altered e.g., in PTHS and schizophrenia (and not categorically qualitatively 
different), the identification and validation of TCF4 target genes in PTHS and corresponding loss-of-
function mouse models could well be of relevance for schizophrenia. The genetic complexity of 
schizophrenia per se and the subtle alterations at the gene expression level that one has to assume to 
occur from the schizophrenia-associated non-coding TCF4 variants obviously hampers the 
identification of target genes from patient derived samples or schizophrenia mouse models. Therefore, 
the fact that different genetic alterations in TCF4 are causally associated with several phenotypically 
overlapping mental disorders could help to guide experimentally feasible attempts to obtain further 
mechanistic insights in the function of this gene. Future studies on TCF4 should thus not strictly focus 
exclusively on models with construct-validity for schizophrenia, which may be out of reach at the 
moment, but should (as the different types of mutations in the gene) step beyond disorder boundaries 
by e.g., analysing genetically defined cellular and animal gain- and loss-of-function models in more 
depth. In addition, observations from human studies could foster translational studies in model 
systems approaching gene*environment interactions with relevance for schizophrenia (see below).  
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By combining electrophysiological measurements with genetics it has been shown that TCF4 risk 
alleles correlate with particular schizophrenia endophenotypes – namely sensory and sensorimotor 
gating [112–114]. Specifically sensory gating revealed an interesting and unexpected 
gene*environment interaction: The schizophrenia risk allele C of the TCF4 rs9960767 SNP was 
robustly associated with reduced P50 suppression of the AEP. However, this genotype effect was 
strongly modulated by smoking behaviour given that only smokers showed reliable TCF4-sensory 
gating associations, while the gene effect was not present in never-smokers. Moreover, the 
genotype*smoking interaction was dose-related as the TCF4 genotype effect grows with increasing 
smoking severity [114]. However, the moderating influence of smoking on the TCF4 genotype effect 
was not present in the previous investigation on TCF4 gene effects on sensorimotor gating measured 
by PPI [113]. The earlier investigated samples might have been too small and underpowered (healthy 
sample: N=98; schizophrenia spectrum sample: N=105) to reliably examine the effects of smoking as 
a mediating factor on the TCF4 gene effects on PPI. The potentially moderating effect of smoking on 
TCF4 gene effects on PPI (and other schizophrenia endophenotypes) should therefore be investigated 
in larger samples. Finally, the TCF4 genotype effect on PPI displayed a much stronger effect size 
(Cohen’s d=0.90) than the mean effect on P50 suppression (mean d=0.23, ranging from 0.03 in never-
smokers to 0.69 in heavy smokers), which could partially be explained by a superior reliability of PPI 
compared to P50 suppression [114]. 
But how could the unexpected smoking*genotype interaction regarding P50 suppression be 
elucidated? There are at least two possible explanations: The first is a hidden gene*gene interaction: In 
this model TCF4 interacts with a hidden gene (or genes) so that only the presence of two or more risk 
alleles is associated with both smoking severity and P50 suppression, while TCF4 alone was merely 
associated with P50 suppression but not with smoking. Further studies might investigate possible 
gene*gene interactions and promising candidates for the “hidden” SNPs may lay in the CHRNA3-
CHRNA5-CHRNB4 gene cluster coding for α3, α5, and β4 nicotinic acetylcholine receptor (nAChR) 
subtypes. SNPs from this gene cluster were reliably associated with smoking behaviour [186–190], 
and also with sensorimotor gating (PPI) [191] and cognitive performance [192]. The second and 
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maybe more appealing explanation for the present result pattern could be a gene*environment 
interaction, in which smoking represents a long-lasting and ongoing environmental influence. This 
interpretation would be in line with the suggestion of Williams et al [41] that the TCF4 schizophrenia 
risk allele may exert its effect on expression exclusively in a developmental context because their 
post-mortem data suggested that this SNP is neither functional nor affects mRNA expression in the 
adult human brain. However, at the moment we can only hypothesize, which neurobiological 
mechanisms might underlie this TCF4*smoking interaction on P50 suppression. Using TCF4 knock-
out mice it was recently shown that TCF4 plays a unique role in the development of the pontine nuclei 
[151]. These nuclei are highly interconnected with the cochlear nucleus and neighboring brain stem 
nuclei that are critically involved in auditory information processing [193, 194]. Moreover, pontine 
nuclei are also connected to the pedunculopontine nucleus [195], which has been shown to be 
critically involved in auditory sensory gating and sensorimotor gating in animal studies [196–199]. 
Most of the auditory pathways within the brain stem are mediated by cholinergic neurotransmission 
and the predominant nAChR expressed in the lower auditory brainstem nuclei is the α7 subtype, while 
α3β4 nAChR also plays a role but rather in the development of the auditory brainstem system [200]. 
Given that repeated exposure to nicotine results in nAChR desensitization [201, 202] and also to a 
long-term homeostatic increase of α4β2 and α7 nAChR [203, 204], smoking-induced changes in 
brainstem nAChR function might interact with developmental changes within pontine nuclei resulting 
in changes of P50 suppression. Actually, P50 amplitude to S1 was influenced by smoking but not by 
TCF4 genotype and, therefore, basic auditory processing was somewhat affected by smoking but not 
directly influenced by TCF4. Moreover, changes in nAChR function induced by chronic nicotine 
exposure might impact auditory sensory gating also at neocortical or hippocampal levels [205]. Taken 
together, smoking-induced plasticity of nAChR in concert with neurodevelopmental changes induced 
by TCF4 gene variations may have affected P50 suppression in our sample. Alternatively, nicotine 
may be involved in the methylation of DNA sequences within the TCF4 gene or other genes 
interacting with TCF4 leading to an epigenetic change of the expression of the corresponding genes. It 
was previously shown that nicotine could decrease glutamic acid decarboxylase-67 and DNA 
methyltransferase-1 via epigenetic mechanisms, which are induced by an activation of nAChRs 
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located on cortical and hippocampal GABAergic interneurons [206]. Additionally, it has been 
recently demonstrated that smoking affects monoaminooxidase-A (MAOA) promoter methylation in 
DNA prepared from lymphoblasts and whole blood [207]. Interestingly, quitting smoking did not lead 
to a return to methylation levels found in never-smokers indicating a long-lasting effect of smoking on 
DNA methylation. Thus, smoking might exert a sustained impact on central MAOA activity (and other 
genes) via epigenetic mechanisms leading to changes in noradrenergic function that interact with 
neurodevelopmental changes caused by TCF4 gene variations (see above). Eventually, nicotine might 
impact the expression of TCF4 gene also directly with functional consequences on early information 
processing. In summary, the unexpected findings in humans of TCF4*smoking interactions inspired 
the formulation of several hypotheses linking different biological systems as additional modulators of 
TCF4-associated endophenotypes i.e. information processing and cognition. These, in turn, could be 
further investigated in Tcf4tg mice which display complementary endophenotypes and may offer 
predictive value for validation and possible pre-clinical studies [112, 119]. Ameliorating the cognitive 
impairments in schizophrenia, most likely caused by higher order information processing deficits in 
dispersed brain circuits, still represents a critical unmet medical need to finally improve the 
therapeutic options for most schizophrenic patients. The elucidation of dedicated TCF4 risk variant-
associated endophenotypes and corresponding molecular mechanisms certainly represent first steps 
towards this goal. 
 
Conclusions 
TCF4 is still one of the most promising schizophrenia risk genes as it is slightly but replicable 
associated with the illness, it is more strongly related to gating endophenotypes of schizophrenia, and 
it seems to be susceptible for environmental impact as discussed above. Moreover, it obviously plays 
an important role in brain development and is connected to the function of other genes such as miR-
137, which are also discussed as schizophrenia risk genes. Taken together, a causal role of TCF4 for 
schizophrenia would be in line with neurodepelopmental hypotheses as well as with repeated-hit 
models and G*E interaction models. Thus, TCF4 as a schizophrenia risk gene would be versatile 
model that has the potential to integrate several schizophrenia models previously suggested. However, 
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the small gene effects in large schizophrenia patient populations and the stronger gene effects 
regarding gating endophenotypes might indicate that there is a subgroup of patients, in which TCF4 
plays a major role during pathogenesis, while most of the patients have different pathogenic pathways. 
Thus, future research might accomplish the identification of a specific TCF4-lead schizophrenia by 
combining genotying and (endo)phenotyping. Finally, it is also conceivable that a combination of risk 
genes ranging from the TCF4 associated bHLH system including interaction partners and target genes 
as well as associated regulatory mechanisms such as miR-137 and possibly Ca2+ linked signalling 
networks, could represent a ‘TCF4 gene-set’ regulating neuronal growth and differentiation in a highly 
redundant network. These genes might cooperatively be responsible for the pathogenesis within a 
subgroup of schizophrenia patients. Due to the high functional redundancy in this network a critical 
mass of genetically and environmentally induced dysfunction is needed before the systems breaks 
down. Thus, we might focus on gene sets within the bHLH system and neighbouring regulatory 
systems to identify patients with a strong genetic and developmental pathogenesis. A postulated TCF4 
associated network of risk factors might potentially be suitable as an early indicator for a 
schizophrenic subtype. When combined with electrophysiological gating measures (such as PPI or P50 
suppression), smoking behaviour and cognitive performance, corresponding molecular profiling could 
guide future stratified sub-population directed therapies. 
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Figure Legends 
 
Fig. 1 Different bHLH transcription factors direct central nervous system (CNS) development at 
embryonic stages and may be involved in adult brain plasticity. Inhibitory bHLH factors (HES1, 
ID1) and proneural factors ATOH1, ASCL1 and NEUROG1,2 as well as E-proteins TCF3 and TCF12 
are involved in early developmental stages. The temporal expression patterns and mutational analyses 
of the neurogenic differentiation factors (NEUROD1,2 and 6) and inhibitors of differentiation ID2 and 
ID4 suggest rather a function in later stages of neuronal differentiation and in the adult CNS. The 
spatiotemporal expression pattern of Tcf4 overlaps substantially with all other bHLH factors involved 
in brain development. Moreover, TCF4 is capable of forming hetero-dimers with most involved 
neuron expressed bHLH factors although direct evidence is thus far only available for NEUROD1 and 
-2 (as indicated by a solid in contrast to dashed lines). It should be noted that this schematic drawing is 
thought to be an overview representation not claiming detailed spatial and temporal expression 
domains of single genes (for citations see main text). 
 
Fig.2 Phenotypical comparisons reveal different TCF4 gene dosage dependences in mice (A) and 
humans (B) in neurodevelopment related diseases including schizophrenia. Gain-of-function and 
loss-of-function analyses in mice and corresponding risk alleles and mutations in humans suggest that 
TCF4 expression differences are tolerated in a narrow range (range depicted in light blue). Exceeding 
critical thresholds increases disease risks (depicted in grey). Slightly increased postnatal expression of 
Tcf4 has been found to cause schizophrenia (SZ) associated symptoms in mice. Phenotypic 
consequences of increased Tcf4 expression during embryonal stages are not known yet (A). Indirect 
evidence from human post-mortem brain and blood sampling suggests that elevated expression may be 
associated with SZ and bipolar disease (BD). The critical period of enhanced TCF4 expression in 
humans is unknown (B). The tolerance range for reduced gene dosage effects might potentially be 
higher in mice compared to humans since heterozygous animals appear to be largely unaffected 
although a thorough behavioral phenotyping has not been performed so far. Thus, it is unknown if 
reduced gene dosage in mice may cause SZ-like symptoms. The analysis of null mutants is hampered 
by perinatal lethality but structural deficits in brain development have been described already although 
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not representing Pitt-Hopkins like symptoms thus far (A). Loss-of-function of TCF4 
(haploinsufficiency and mosaic deficiency) causes severe neurodevelopmental diseases including 
PTHS and possibly other autism-like syndromes. Given many examples of inverted-U-shape 
relationships of gene dosage with disease severity in autism-related neurodevelopmental diseases, it 
appears possible that slightly reduced expression levels of TCF4 may be implicated in SZ (B) (for 
citations see main text). SZ, schizophrenia; BD, bipolar disorder; PTHS, Pitt-Hopkins Syndrome; 
NDD, neurodevelopmental disorder; MR, mental retardation. 
 
Fig. 3 Brain structures involved in postulated deficits of information processing in mice and 
men. Behavioural and neuropsychological phenotypes obtained in mice (A) and human subjects (B) 
suggest a function of TCF4 in brain networks that are important for cognition (bold lines) and sensory 
processing (dotted grey lines). Deregulation of TCF4 expression levels during development interferes 
with proper functional connectivity within corresponding brain networks (for citations see main text). 
ACx, auditory cortex; Amy, amygdala; Hi, hippocampus; NAc, nucleus accumbens; PCx, prefrontal 
cortex; PPN, pedunculopontine nucleus; VTA, ventral tegmental area; VP, ventral pallidum;  
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Table 1: Single nucleotide polymorphisms of the transcription factor 4 (TCF4) associated with schizophrenia and schizophrenia endophenotypes 
 
Phenotype / endophenotype TCF4 SNPs Significant 
association with 
minor allele
Study type and samples Ethnicity References
Schizophrenia rs9960767
 
ORc = 1.20-1.23
 
GWASa with partially overlapping 
samples: 
12945 to 18206 SZ patients 
34591 to 42536 controls 
European ancestry 
(also including 
European-
Americans and 
European -
Australians) 
Stefansson et al. 2009 [76] 
 
rs17512836
 
OR = 1.23
 
Ripke et al. 2011 [19] 
 
rs4309482 OR = 1.09 Steinberg et al. 2011 [77] 
 
Schizophrenia rs2958182 OR = 0.78 Single association study: 
2496 SZ patients 
5184 controls
Han Chinese Li et al. 2010 [78] 
Schizophrenia rs9960767
 
OR = 1.18
 
GWAS:
1606 SZ patients 
1794 controls 
Irish Strange et al. (2012) [79] 
rs17594526d OR = 1.77
Schizophrenia rs1261117 OR = 1.6 Family-based linkage meta-analysis:
6298 individuals (including 3286 SZ 
patients) from 1811 nuclear families
European ancestry Aberg et al. 2013 [80] 
Multivariate schizophrenia 
phenotype including positive, 
negative, and cognitive 
symptoms, neurological soft 
signs, and age of prodromal 
onset 
rs9960767
 
Risk allele C was  
associated  with 
more pronounced 
schizophrenia 
phenotype (only 
trend, not 
surviving 
correction for 
multiple testing)
Phenotype-based association study:
1041 SZ patients 
1144 controls 
German Papiol et al. 2011 [82] 
Antipsychotic drug response in 
SZ patients 
rs9960767 No effect Pharmacogenetic association study:
214 SZ patients in total (two independent 
samples wit N=70 and N=144 SZ patients)
German Lennertz et al. 2011 [84] 
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Prepulse inhibition of the 
acoustic startle response 
(sensorimotor gating) 
rs9960767 Risk allele was 
associated with 
schizophrenia-
like 
endophenotype 
ORe = 6.82 (SZ) 
ORe = 4.93 
(controls) 
ORe = 4.81 (total 
sample)
Endophenotype-based association study in 
two independent samples: 
105 SZ patients and high risk subjects 
98 controls 
SZ patients: German
Controls: British 
Quednow et al. 2011 [113] 
P50 suppression of the auditory 
evoked potential (sensory 
gating) 
rs9960767
rs17512836 
rs17597926d 
rs10401120 
 
Risk alleles were 
associated with 
schizophrenia-
like 
endophenotype 
ORe = 1.23-1.46 
(never-smokers) 
ORe = 2.10-2.44 
(light smokers) 
ORe = 3.21-5.50 
(heavy smokers) 
ORe = 1.81-1.94 
(total sample)
Endophenotype-based association study:
1821 controls 
German Quednow et al. 2012 [114] 
Word recognition rs9960767
 
Risk allele C was 
associated with 
enhanced 
performance
Endophenotype-based association study:
401 SZ patients 
German Lennertz et al. 2011 [127] 
Attention and vigilance
Working memory 
Processing speed 
Visuo-motor speed/set-shifting 
Verbal fluency 
rs9960767
 
No effect Endophenotype-based association study:
198 SZ patients 
205 controls 
German Lennertz et al. 2011 [84] 
Verbal fluency rs12966547 
rs4309482
Risk alleles were 
associated with 
Endophenotype-based association study:
596 psychotic patients (including patients 
Norwegian Wirgenes et al. 2012 [83] 
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poor performance with SZ, bipolar disorder, or other 
psychoses) 
385 controls
Intelligence Test (WAIS-RCf) 
Several attention-related tasks 
rs2958182 Risk allele was 
associated with 
better 
performance in 
patients but 
worse in controls
Endophenotype-based association study:
580 SZ patients 
498 controls 
Han Chinese Zhu et al. 2013 [128] 
Reasoning and problem solving 
Processing speed 
rs9960767
 
Risk allele was 
associated with 
lower 
performance
Endophenotype-based association study:
173 first-episode psychosis patients 
 
Canadian Albanna et al. 2013 [129] 
aGWAS: Genome-wide association study 
bSZ: Schizophrenia 
cOR: Odds ratio 
dThis SNP was also among the top ten significant TCF4 SNPs in the so far largest megalo-GWAS-analysis of Ripke et al. (2011) [19]. 
eCriterion one standard deviation from the control population 
fWechsler Adult Intelligence Scale-Revised 
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